Oncology consultancy company Physiomics (LON: PYC) shares are gaining slightly on Tuesday after the company revealed it has been awarded a first contract by new client Numab Therapeutics.
On Monday, Physiomics share price fell over 8.5% after it provided a trading update, lowering guidance after Covid related project delays.
Today, it has begun to claw back some of those losses, trading at 5.95p, up 1.71%.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Get up to £500 cashback for investing with IG.
Numab Therapeutics is a biopharmaceutical company based in Zurich, Switzerland, developing multi-specific biotherapeutics for chronic inflammation and cancer.
Physiomics said it has “recent significant experience of the mathematical modelling of multi-specific pharmaceuticals which it will bring to bear on an undisclosed Numab compound in this project that is expected to last around three months.”
“We are delighted that Numab has selected Physiomics to support them with one of their new programs and look forward to working with their highly talented team,” said the AIM-listed company’s CEO, Dr Jim Millen.
Should you invest in Physiomics shares?
Physiomics shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Physiomics shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies